An AI-integrated cloud-based Clinical Data Trial System (CDTS) for a novel retinal biomarker

用于新型视网膜生物标志物的人工智能集成云临床数据试验系统（CDTS）

• 批准号: 81493
• 金额: $ 16.74万
• 依托单位: NOVAI LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=81493
• 关键词: AI; integrated; cloud; based; Clinical

**Public Description**Novai Ltd. is a rapidly growing UK-SME specialising in biotechnology and data science. Novai was founded by Dr John Maddison, Professor Francesca Cordeiro and Aman Khan; the founders have 20 years' experience in the development and management of impactful and clinical projects. There is an unmet need in accelerating and de-risking drug development for blinding ophthalmic diseases. Current diagnostics and endpoints rely on observing structural or visual function changes, both of which take years to manifest. Novai will work to develop a Clinical Data Trials System (CDTS) integrated with AI on a cloud-based system using a novel retinal biomarker.

** 公开描述 **Novai Ltd.是一家快速发展的英国中小企业，专注于生物技术和数据科学。Novai由John Maddison博士，Francesca Cordeiro教授和Aman Khan创立;创始人在开发和管理有影响力的临床项目方面拥有20年的经验。在加速用于致盲性眼科疾病的药物开发和降低其风险方面存在未满足的需求。目前的诊断和终点依赖于观察结构或视觉功能的变化，这两者都需要数年时间才能显现。Novai将致力于开发一个临床数据试验系统（CDTS），该系统使用一种新的视网膜生物标志物，在基于云的系统上与AI集成。